We focus on “hard targets” in cancer and autoimmune disease with strong biological validation that have not been successfully drugged
We deploy our proprietary Rational Antibody Discovery platform to discover and engineer precision therapies, unlocking the therapeutic potential of these targets
Pipeline & Partners
Hummingbird Bioscience Presents Pre-Clinical Data on its Next-Generation BCMA-TACI Dual-Specific T Cell...
10 April 2021